UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Before investing in 2023, it's vital to learn key concepts. Equip yourself with knowledge to ensure smart investment choices.
17,856 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Rivian readies its lower-cost R2 for April deliveries, a pivotal move as analysts weigh its power to expand beyond pr...
Non-US markets rebound as the dollar weakens, prompting retirees to seek ESG-friendly exposure that also delivers div...
Greg Abel has stepped into Berkshire Hathaway’s top role with a plan that blends steady operations with a measured ap...
Stoneridge is navigating a pivotal year as auto production and tech content rise. This guide breaks down what to expe...
Palantir reports strong government revenue growth while warning that adversaries are increasingly targeting AI data c...
The Ethereum Foundation has quietly moved 5,000 ETH to BitMine in a $10 million over-the-counter trade, marking its s...
If you want steady income and long-term growth, these five dividend stocks right now combine durable dividends with s...
A 2,000-year GDP chart is fueling debate about long-run shifts in economic power. Dalio’s pattern idea is driving fre...
Gold prices lure investors to miners as a way to gain leveraged exposure to gold. This article compares two different...
DeFi founders argue that tokenized assets are the next growth lever, linking real-world value to on-chain liquidity. ...
Lamborghini posted a record year for deliveries in 2025, but import tariffs trimmed profits and narrowed margins. The...